Clomiphene Citrate interactions
Checked as Clomifene in this data source.
Full monograph for Clomiphene CitrateCheck it against another medicine
Medicines
1 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Ospemifenematched approximately | Moderate | Others | The concurrent use of ospemifene with estrogens or other estrogen agonists/antagonists has not been evaluated. Safety and efficacy of this combination are… | 5 sources — open the full entry |
Conditions
Conditions in which Clomiphene Citrate needs care, as documented in this source.
Adrenal Insufficiency
MajorThe use of clomiphene is contraindicated in patients with uncontrolled adrenal function. Alterations of adrenal function can impede pregnancy. Clomiphene therapy can result in alteration in steroid synthesis and/or fluid regulation.
1 source
- "Product Information. ClomiPHENE Citrate (clomiPHENE)." Teva Pharmaceuticals USA (2022):
Liver Diseases
MajorThe use of clomiphene is contraindicated in patients with liver disease or history of hepatic dysfunction.. Clomiphene undergoes enterohepatic circulation and is metabolized by the liver. The serum concentration of clomiphene may be increased and the half-life prolonged in patients with compromised hepatic function.
1 source
- "Product Information. ClomiPHENE Citrate (clomiPHENE)." Teva Pharmaceuticals USA (2022):
Metrorrhagia
MajorThe use of clomiphene is contraindicated in patients with undiagnosed, abnormal genital bleeding. Patients should be evaluated to ensure that neoplastic lesions are not present.
1 source
- "Product Information. ClomiPHENE Citrate (clomiPHENE)." Teva Pharmaceuticals USA (2022):
Pituitary Diseases
MajorThe use of clomiphene is contraindicated in patients with uncontrolled thyroid or adrenal dysfunction or an organic intracranial lesion such as a pituitary tumor. Clomiphene interacts with estrogen receptors in various tissues, including the pituitary, the response of which is an increase in the release of pituitary gonadotropins.
1 source
- "Product Information. ClomiPHENE Citrate (clomiPHENE)." Teva Pharmaceuticals USA (2022):
Hyperlipidemias
ModerateCases of hypertriglyceridemia have been reported in patients receiving clomiphene treatment. Preexisting or family history of hyperlipidemia and use of higher than recommended dose and/or longer duration of treatment with clomiphene citrate are associated with a risk of hypertriglyceridemia. Periodic monitoring of plasma triglycerides is recommended in patients with preexisting or family history of hyperlipidemia. Pretreatment screening of triglyceride levels is recommended in patients initiating clomiphene citrate therapy.
1 source
- "Product Information. ClomiPHENE Citrate (clomiPHENE)." Teva Pharmaceuticals USA (2022):